Salute e Benessere
Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
Discover the mismatch repair deficiency new treatment @
Mismatch repair deficiency is a hallmark of various cancers, including colorectal, endometrial, and gastric cancers. The increasing incidence of these cancers has heightened the demand for targeted therapies.
The approval of immune checkpoint inhibitors (ICIs), such as , for treating dMMR cancers has revolutionized treatment approaches. These therapies exploit the high mutational burden in dMMR tumors to enhance immune system targeting. The pan-tumor indication for immunotherapy in dMMR/MSI-H cancers has broadened treatment options and emphasized the importance of biomarker testing.
The treatment pipeline for dMMR is strong, with new therapies in development, such as combined with (Arcus Biosciences/Gilead Sciences), (Novartis), (Medicenna Therapeutics), (Roche), and others, aimed at delivering safe and effective therapeutic options.
dMMR/MSI-H cancers continue to represent a high-value segment in immuno-oncology, driven by widespread testing and durable responses to PD-1 inhibitors. On the commercial front, (pembrolizumab, Merck) anchors the space with its tumor-agnostic US approval now fully implemented, allowing treatment across unresectable or metastatic MSI-H/dMMR solid tumors. (nivolumab, BMS), including the nivolumab + ipilimumab combination, has expanded in dMMR/MSI-H metastatic colorectal cancer, reinforcing PD-1 leadership. Approvals of (GSK) and (AstraZeneca) in dMMR endometrial cancer are moving checkpoint therapy earlier in treatment lines and into combination regimens, broadening the patient population.
Looking forward, competition is intensifying with next-generation combinations such as (anti-PD-1) + (anti-TIGIT) and novel mechanisms like (Novartis), a first-in-class WRN helicase inhibitor matched to MSI-H/dMMR tumors. As MSI testing penetration grows and multiple first-line and peri-operative studies report outcomes, revenue is expected to remain robust despite PD-1 class crowding. Key differentiators will be earlier-line use, combination efficacy, and biomarker-guided patient selection. Challenges include pricing pressure, biosimilar competition, and intellectual property considerations around formulation lifecycle strategies. Overall, the dMMR/MSI-H franchise is positioned for continued growth and label expansion across multiple tumor types.
To know more about mismatch repair deficiency treatment options, visit @
The pipeline for treating dMMR is robust, with emerging therapies such as (Arcus Biosciences/Gilead Sciences), (Novartis), (Medicenna Therapeutics), (Roche), and others currently in development to provide safe and effective treatment options.
, a PD-1 inhibitor, and domvanalimab, a TIGIT inhibitor, are being developed by Arcus Biosciences in partnership with Gilead and are under investigation as a combined dual checkpoint blockade therapy. Zimberelimab works by reactivating T-cells through PD-1 inhibition, while domvanalimab targets the TIGIT pathway. This dual immunotherapy approach is also being evaluated in biomarker-selected cancers, including those with dMMR or MSI-H.
, is a first-in-class WRN helicase inhibitor aimed at treating cancers with dMMR and MSI-H. Tumors with these features accumulate DNA errors and rely heavily on WRN helicase for survival, creating a synthetic lethality opportunity. By selectively inhibiting WRN, HRO761 is intended to eliminate dMMR/MSI-H tumor cells while minimizing effects on normal tissue, providing a targeted therapy option beyond conventional immunotherapy.
The anticipated launch of these emerging therapies are poised to transform the mismatch repair deficiency market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the mismatch repair deficiency market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for mismatch repair deficiency @
dMMR describes a malfunction in the cellular system that corrects errors occurring during DNA replication. Normally, the mismatch repair (MMR) mechanism detects and fixes mismatched base pairs or small insertions/deletions that arise during DNA synthesis or recombination. When this system loses functionality, DNA mutations accumulate, leading to genomic instability and a higher risk of cancer.
Diagnosis of dMMR involves examining tumor tissue for the absence of key MMR proteins (MLH1, MSH2, MSH6, PMS2) through immunohistochemistry or assessing microsatellite instability (MSI) via molecular tests. If dMMR is found, additional analyses, such as MLH1 promoter methylation or BRAF mutation testing, help differentiate between hereditary and sporadic cases. Germline genetic testing can confirm inherited syndromes like Lynch syndrome. This stepwise diagnostic process enables accurate identification of dMMR, informs cancer treatment decisions, and provides important information about familial risk.
The mismatch repair deficiency epidemiology section provides insights into the historical and current mismatch repair deficiency patient pool and forecasted trends for the leading markets. Endometrial cancer has the highest rate, with dMMR found in about of cases, and some reports up to .
The mismatch repair deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving mismatch repair deficiency therapeutics market trends @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CRC companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including , among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including , among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ovarian cancer companies, including , among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mismatch-repair-deficiency-market-forecasts-strong-expansion-during-the-forecast-period-20252034-driven-by-rising-diagnostics-and-immuno-oncology-advances--delveinsight-302591008.html